BELLEVUE, Wash.d--(BUSINESS WIRE)--Sept. 22, 2006--SCOLR Pharma, Inc. (Amex: DDD) announced today that it has entered into a research collaboration with a US based biopharmaceutical company to develop an oral formulation of a promising antiviral compound using SCOLR’s proprietary CDT(R) drug delivery platform. The compound under development has the potential to be used as a treatment against influenza. The goal of the program is to enhance the bioavailability of our partner’s compound to facilitate oral administration. If successful, the parties expect to enter a license agreement which would provide for the potential commercialization of a significant new pharmaceutical product.
